A hospitalist rapid-management guide — recognize it, hit the one-hour antibiotic, score the risk, and know when to add MRSA or antifungal coverage. An oncologic emergency where minutes matter.
Fever: a single oral temp ≥ 38.3 °C (101 °F), or ≥ 38.0 °C (100.4 °F) sustained ≥ 1 h.
Neutropenia: ANC < 500/µL, or < 1000 with a predicted fall to < 500 within 48 h. Profound < 100; prolonged > 7 days (higher risk).
Neutropenia blunts inflammation — there may be no pus, infiltrate, or localizing signs, and the patient can be afebrile yet septic (hypothermia or hypotension may be the only clue). Treat as an emergency regardless.
Low risk (MASCC ≥ 21) may be eligible for oral / outpatient therapy — but ONLY with all of: able to tolerate oral, no focal/serious infection, no significant comorbidity, reliable caregiver + transport, and close follow-up. When in doubt, admit. Most inpatients are high risk. (CISNE is an alternative score in clinically stable solid-tumor patients.)
Monotherapy with an antipseudomonal β-lactam — give the first dose within 60 minutes:
Vancomycin (or linezolid / daptomycin) if: hemodynamic instability · suspected catheter-related infection · skin/soft-tissue infection · pneumonia · known MRSA/VRE colonization · severe mucositis · gram-positive cocci in blood cultures pending ID. Reassess at 48 h and STOP if not confirmed.
Non-severe: cefepime or a carbapenem is usually fine. Severe/anaphylaxis: aztreonam + vancomycin (± aminoglycoside), or ciprofloxacin + vancomycin.
Ciprofloxacin + amoxicillin-clavulanate — only if not on fluoroquinolone prophylaxis and the low-risk criteria above are met.
If fever persists or recurs after 4–7 days of broad-spectrum antibiotics with expected prolonged neutropenia (> 7 days), add empiric antifungal and investigate for invasive fungal disease.
Agents: echinocandin (caspofungin / micafungin) or liposomal amphotericin B; voriconazole if mold / aspergillus is suspected.
Work up: CT chest ± sinuses, serum galactomannan and β-D-glucan, repeat cultures. Think invasive candidiasis and aspergillosis.
Traditional: continue broad-spectrum until ANC ≥ 500/µL and rising AND afebrile ≥ 48 h.
Newer option (ECIL-4 / the "How Long" RCT): in a patient hemodynamically stable since presentation and afebrile ≥ 48 h (after ≥ 72 h of therapy), antibiotics may be stopped regardless of the neutrophil count — with close monitoring and prompt restart if fever recurs. Lowers antibiotic exposure.
Treat for the pathogen / site's standard course (e.g., Gram-negative bacteremia ~7–14 days by organism and source — about 7 days for uncomplicated GNB with source control; S. aureus bacteremia longer), and generally continue at least until count recovery if still neutropenic. Remove infected lines for the right organisms.
Low-risk patients only. Once afebrile, hemodynamically stable, and tolerating/absorbing oral, step down to ciprofloxacin + amoxicillin-clavulanate (if not on FQ prophylaxis) and complete as an outpatient with close follow-up.
Do NOT step down with: high-risk / profound-prolonged neutropenia, hemodynamic instability, a documented infection that needs IV, or mucositis/ileus impairing absorption. High-risk patients stay IV until count recovery.
De-escalate (narrow) by 48–72 h on cultures — stop empiric vancomycin if no Gram-positive indication; narrow to the pathogen. This is separate from the stop/duration rules above.
G-CSF is not routine for established neutropenic fever — consider for high-risk features (expected prolonged profound neutropenia, sepsis, pneumonia, invasive fungal) or next-cycle prophylaxis.
Med Topo · Tools — an educational rapid-reference for the common case; not a substitute for IDSA/NCCN/ASCO guidelines, oncology/ID input, or clinical judgment. Verify every dose and individualize to the patient, renal/hepatic function, local antibiogram, and institutional protocol. · Back to Tools